Overall, MET-097is high half-life and potential once monthly dosing is a key differentiator in the space, and it boasts strong early signals of efficacy
Notably, GGCT knockdown markedly altered mitochondrial morphology and impaired oxidative phosphorylation and glycolysis capacity
Practices that prepare early may adapt more smoothly as the market evolves
Safety Winner: Semaglutide GLP-1 RAs in general have a lower side effect risk than tesamorelin, and the literature currently favors semaglutides safety profile over that of tirzepatide
In 2023, the FDA launched an investigation after GLP-1 agonist users started reporting thoughts of suicide as of January 2024, it hadnt found anything to confirm the connection, but it also said it couldnt yet rule it out, meaning its possible the drugs could cause mental health issues for some people, rather than treating or preventing them
Diabetes Care 32 , 8490 (2009)